[THE INVESTOR] Daewoong Pharmaceutical is right on track for launching its botulinum toxin Nabota in the US, said Korea Investment and Securities on Nov. 20 maintaining a “buy” recommendation and 230,000 won (US$203.90) target price.
Its US partner Evolus has gained conditional acceptance from the US Food and Drug Administration to use Jeuveau brand name for Nabota, said analyst Jin Heung-guk, adding that final sales approval is likely by February.
It is likely to be a success, as Allergan, maker of Botox, has predicted that copy drugs in the US will expand their market share to 13 percent by 2025 from the current 7 percent. Nabota’s sales will top US$8 million next year and US$44 million in 2020. Its market share will peak at 15 percent in 2025, the analyst estimated.
By Hwang You-mee (firstname.lastname@example.org)